Investigative Ophthalmology & Visual Science · 2017 · 43 citations · 28 references
MedicineOphthalmologyVision ScienceBiomedical OpticsOcular ImagingOphthalmic SurgeryCorneal AnatomyCorneal BiomechanicsCorneal ImagingCorneal OpticsCorneal PhysiologyBiomechanical Corneal AssessmentBiomechanical TestingCollagen Cross-linking ChangesCorneal Biomechanical EffectsCorneal Cross-linking BiomechanicsCorneal Deformation ResponseEx Vivo Corneal ModelsFinite Element Modeling
Purpose: To compare corneal biomechanical properties after in vivo and ex vivo cross-linking (CXL) using rose bengal-green light (RGX) or riboflavin-UVA (UVX). Methods: Corneas of 30 rabbits were treated in vivo by the two CXL modalities monolaterally (Group 1) or bilaterally (Group 2). Rabbits in Group 1 were euthanized 1 month after treatments and in Group 2 two months after treatment. Ex vivo CXL was also performed. Eyes were measured by Scheimpflug air puff corneal deformation imaging (Corvis ST) under constant IOP. Corneal deformation parameters were assessed. Inherent corneal biomechanical properties were estimated using inverse finite element modeling. Results: Peak to peak distance decreased 16% 2 months after RGX, and 4% and 20% 1 and 2 months after UVX, respectively. The equivalent Young's modulus (Eeq) increased relative to the control during the post treatment period for both RGX and UVX. The Eeq increased by factors of 3.4 (RGX) and 1.7 (UVX) 1 month and by factors of 10.7 (RGX) and 7.3 (UVX) 2 months after treatment. However, the Eeq values for ex vivo CXL were much greater than produced in vivo. The ex vivo Eeq was greater than the 1-month in vivo values by factors of 8.1 (RGX) and 9.1 (UVX) and compared with 2 month by factors of 2.5 (RGX) and 2.1 (UVX). Conclusions: These results indicate that corneal stiffness increases after CXL, and further increases as a function of time after both RGX and UVX. Also, while biomechanical properties determined after ex vivo CXL are indicative of corneal stiffening, they may not provide entirely accurate information about the responses to CXL in vivo.
28
Risk factors for progression to penetrating keratoplasty in patients with keratoconus.
Sherman W. Reeves, Sandra S. Stinnett, Ron A. Adelman et al. · PubMed · 2005 · 290 citations
Medicine, Ophthalmology, Surgery +10